Movement Alert｜Caris Life Sciences, Inc. Falls 5.05% in Regular Trading, Profit-Taking Emerges After BofA Target Price Increase

Market Focus10-17 03:10

On October 17, Caris Life Sciences, Inc. fell 5.05% in Regular Trading, trading at $30.24 per share, with turnover of $54.28 million.

The latest market-moving development points to short-term profit-taking after a recent rally, even though BofA Securities had raised its target price to $35 from $23, above the broader analyst average target of $27.08.

Recent fundamentals had been supportive: second-quarter revenue reached $263.712 million, above the $238.125 million consensus, while first-quarter revenue rose 79% year over year to $216.2 million and the company reported breakeven results versus an expected loss. Management also reaffirmed full-year revenue guidance of $1.0 billion to $1.02 billion, with the next earnings release scheduled for November 4.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment